Table 3.

Crude and overlap propensity score weighted odds ratios of dates of statin prescription for malignant brain tumors.

Characteristics	N of Brain Tumors	N of Controls	Odds Ratios for Malignant Brain Tumors (95% Confidence Interval)
	(Exposure/Total, %)	(Exposure/Total, %)	Crude	p-Value	Overlap Weighted Model †	p-Value
Dyslipidemia and Any statin prescription
Normal	725/1072 (67.63)	2596/4288 (60.54)	1		1
Dyslipidemia without statin	158/1072 (14.74)	995/4288 (23.2)	0.57 (0.47–0.69)	<0.001 *	0.65 (0.56–0.75)	<0.001 *
Dyslipidemia with <365 days	88/1072 (8.21)	278/4288 (6.48)	1.13 (0.88–1.46)	0.333	1.61 (1.29–2.00)	<0.001 *
Dyslipidemia with ≥365 days	101/1072 (9.42)	419/4288 (9.77)	0.86 (0.68–1.09)	0.214	1.10 (0.91–1.34)	0.309
Dyslipidemia and Lipophilic statin prescription
Normal	725/1072 (67.63)	2596/4288 (60.54)	1		1
Dyslipidemia without Lipophilic statin	189/1072 (17.63)	1150/4288 (26.82)	0.59 (0.49–0.70)	<0.001 *	0.69 (0.60–0.79)	<0.001 *
Dyslipidemia with <365 days	83/1072 (7.74)	253/4288 (5.9)	1.17 (0.90–1.53)	0.227	1.71 (1.36–2.15)	<0.001 *
Dyslipidemia with ≥365 days	75/1072 (7.00)	289/4288 (6.74)	0.93 (0.71–1.21)	0.59	1.09 (0.88–1.35)	0.407
Dyslipidemia and Hydrophilic statin prescription
Normal	725/1072 (67.63)	2596/4288 (60.54)	1		1
Dyslipidemia without Hydrophilic statin	285/1072 (26.59)	1467/4288 (34.21)	0.70 (0.60–0.81)	<0.001 *	0.82 (0.73–0.93)	0.002 *
Dyslipidemia with <365 days	42/1072 (3.92)	113/4288 (2.64)	1.33 (0.93–1.92)	0.123	1.75 (1.27–2.41)	<0.001 *
Dyslipidemia with ≥365 days	20/1072 (1.87)	112/4288 (2.61)	0.64 (0.39–1.04)	0.07	0.92 (0.64–1.34)	0.676

Abbreviations: CCI, Charlson Comorbidity Index; * Significance at p < 0.05; † Adjusted for age, sex, income, region of residence, diabetes history, CCI scores, and diabetes.